Trail Ridge Investment Advisors LLC Has $437,000 Stock Position in Zoetis Inc. (NYSE:ZTS)

Trail Ridge Investment Advisors LLC lowered its stake in Zoetis Inc. (NYSE:ZTS) by 48.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,626 shares of the company’s stock after selling 2,497 shares during the quarter. Trail Ridge Investment Advisors LLC’s holdings in Zoetis were worth $437,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after acquiring an additional 112 shares during the last quarter. Worth Asset Management LLC acquired a new position in Zoetis during the first quarter worth approximately $26,000. HHM Wealth Advisors LLC increased its position in Zoetis by 1,160.0% during the first quarter. HHM Wealth Advisors LLC now owns 189 shares of the company’s stock worth $31,000 after buying an additional 174 shares during the last quarter. Elequin Securities LLC acquired a new position in Zoetis during the fourth quarter worth approximately $32,000. Finally, Tortoise Investment Management LLC increased its position in Zoetis by 201.5% during the first quarter. Tortoise Investment Management LLC now owns 202 shares of the company’s stock worth $34,000 after buying an additional 135 shares during the last quarter. Institutional investors and hedge funds own 89.47% of the company’s stock.

Zoetis Price Performance

Shares of NYSE:ZTS traded down $0.94 during trading on Friday, hitting $186.84. 353,293 shares of the company were exchanged, compared to its average volume of 1,979,036. The business’s 50 day moving average is $181.91 and its 200-day moving average is $174.52. The company has a market capitalization of $86.01 billion, a P/E ratio of 39.45, a price-to-earnings-growth ratio of 3.01 and a beta of 0.78. The company has a quick ratio of 1.97, a current ratio of 3.50 and a debt-to-equity ratio of 1.42. Zoetis Inc. has a 1-year low of $124.15 and a 1-year high of $194.99.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.10. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.16 billion. Zoetis had a net margin of 26.92% and a return on equity of 52.02%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.20 earnings per share. Equities analysts forecast that Zoetis Inc. will post 5.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ZTS shares. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 2nd. Stifel Nicolaus boosted their price target on Zoetis from $195.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, August 28th. The Goldman Sachs Group boosted their price objective on Zoetis from $204.00 to $213.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. HSBC started coverage on Zoetis in a research note on Wednesday. They issued a “buy” rating and a $230.00 price target for the company. Finally, Piper Sandler boosted their price target on Zoetis from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Monday, August 14th. Ten analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $225.13.

Insider Activity at Zoetis

In related news, CEO Kristin C. Peck sold 13,000 shares of the stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $179.97, for a total value of $2,339,610.00. Following the completion of the sale, the chief executive officer now directly owns 56,843 shares in the company, valued at $10,230,034.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $192.97, for a total value of $178,111.31. Following the completion of the sale, the executive vice president now directly owns 25,434 shares in the company, valued at $4,907,998.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kristin C. Peck sold 13,000 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $179.97, for a total transaction of $2,339,610.00. Following the sale, the chief executive officer now directly owns 56,843 shares in the company, valued at approximately $10,230,034.71. The disclosure for this sale can be found here. Insiders sold 15,102 shares of company stock worth $2,741,661 over the last three months. Company insiders own 0.12% of the company’s stock.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.